Ailiang Zeng

List of Publications by Year in Descending Order

22 papers	931 citations	14 h-index	22 g-index
22 ext. papers	1,193 ext. citations	7.9 avg, IF	4.38 L-index

#	Paper	IF	Citations
22	Qki activates Srebp2-mediated cholesterol biosynthesis for maintenance of eye lens transparency. *Nature Communications*, **2021**, 12, 3005	17.4	5
21	Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p. *Theranostics*, **2021**, 11, 1763-1779	12.1	13
20	Exosomes derived from microRNA-512-5p-transfected bone mesenchymal stem cells inhibit glioblastoma progression by targeting JAG1. *Aging*, **2021**, 13, 9911-9926	5.6	7
19	CircRNACCDC66 regulates cisplatin resistance in gastric cancer via the miR-618/BCL2 axis. *Biochemical and Biophysical Research Communications*, **2020**, 526, 713-720	3.4	22
18	The long noncoding RNA ZFAS1 promotes the progression of glioma by regulating the miR-150-5p/PLP2 axis. *Journal of Cellular Physiology*, **2020**, 235, 2937-2946	7	18
17	Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 166	12.8	103
16	Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. *EBioMedicine*, **2019**, 42, 238-251	8.8	86
15	Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. *Molecular Cancer*, **2019**, 18, 71	42.1	210
14	S100A11 functions as novel oncogene in glioblastoma via S100A11/ANXA2/NF-B positive feedback loop. *Journal of Cellular and Molecular Medicine*, **2019**, 23, 6907-6918	5.6	19
13	Long non-coding RNA SNHG5 promotes glioma progression via miR-205/E2F3 axis. *Bioscience Reports*, **2019**, 39,	4.1	11
12	Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma. *Oncogene*, **2019**, 38, 2706-2721	9.2	23
11	RelB, a good prognosis predictor, links cell-cycle and migration to glioma tumorigenesis. *Oncology Letters*, **2018**, 15, 4404-4410	2.6	5
10	miR-129-5p targets Wnt5a to block PKC/ERK/NF-B and JNK pathways in glioblastoma. *Cell Death and Disease*, **2018**, 9, 394	9.8	62
9	Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. *Cancer Letters*, **2018**, 436, 10-21	9.9	92
8	miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas. *OncoImmunology*, **2018**, 7, e1510277	7.2	12
7	H19 Functions as a Competing Endogenous RNA to Regulate EMT by Sponging miR-130a-3p in Glioma. *Cellular Physiology and Biochemistry*, **2018**, 50, 233-245	3.9	42
6	Genome-wide identification of epithelial-mesenchymal transition-associated microRNAs reveals novel targets for glioblastoma therapy. *Oncology Letters*, **2018**, 15, 7625-7630	2.6	9

5	Polycomb group expression signatures in the malignant progression of gliomas. *Oncology Letters*, **2017**, 13, 2583-2590	2.6	4
4	Fstl1 Promotes Glioma Growth Through the BMP4/Smad1/5/8 Signaling Pathway. *Cellular Physiology and Biochemistry*, **2017**, 44, 1616-1628	3.9	17
3	miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. *Neuro-Oncology*, **2017**, 19, 55-65	1	84
2	MicroRNA-141-3p promotes glioma cell growth and temozolomide resistance by directly targeting p53. *Oncotarget*, **2017**, 8, 71080-71094	3.3	34
1	IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. *Oncotarget*, **2015**, 6, 30232-8	3.3	53